Guided Therapeutics (GTHP) Cash from Operations Growth (3y) (2019 - 2025)
Guided Therapeutics (GTHP) Cash from Operations Growth (3y) (2019 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.94 Bn | 176.64 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 128.78 Bn | 125.90 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 109.01 Bn | 99.79 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 68.59 Bn | 67.13 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 47.66 Bn | 43.99 Bn | 1.29 Bn | -48.14% |
| 6 | GE HealthCare Technologies | 28.36 Bn | 26.07 Bn | 1.98 Bn | -14.75% |
| 7 | Dexcom | 28.30 Bn | 27.18 Bn | 750.30 Mn | 50.11% |
| 8 | Smith & Nephew | 26.93 Bn | 26.36 Bn | - | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.33 Bn | 2.07 Bn | 0.50% |
| 10 | Guided Therapeutics | 20.39 Mn | 20.32 Mn | 458,000.00 | 4.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.96% |
| Sep 30, 2025 | 23.22% |
| Jun 30, 2025 | 21.47% |
| Mar 31, 2025 | -22.74% |
| Dec 31, 2024 | -59.90% |
| Sep 30, 2024 | 13.82% |
| Jun 30, 2024 | 32.38% |
| Mar 31, 2024 | 32.14% |
| Dec 31, 2023 | -0.50% |
| Sep 30, 2023 | 7.93% |
| Jun 30, 2023 | -2.39% |
| Mar 31, 2023 | 1.99% |
| Dec 31, 2022 | -18.45% |
| Sep 30, 2022 | -38.98% |
| Jun 30, 2022 | -22.90% |
| Mar 31, 2022 | 1.27% |
| Dec 31, 2021 | 35.92% |
| Sep 30, 2021 | -21.01% |
| Jun 30, 2021 | -41.94% |
| Mar 31, 2021 | 6.78% |